Should non-diabetic men use a continuous glucose monitor?

CGMs worn by non-diabetic individuals provide information about glucose variability and postprandial responses that standard lab tests cannot capture. This can be clinically informative for men with prediabetes or metabolic syndrome. For healthy metabolically normal men, the clinical utility is less established. The data is potentially useful but requires appropriate interpretation.

What does a CGM show in a healthy person?

In a metabolically healthy person, glucose typically rises after meals then returns to baseline within 2 hours. The CGM shows how different foods affect glucose, whether overnight glucose is stable, and whether exercise produces hypoglycemia or glucose stability. Glucose spikes above 140 mg/dL after meals are considered physiologically abnormal and may indicate impaired glucose tolerance.

Does wearing a CGM reduce heart disease risk?

There is no clinical trial evidence that CGM use in non-diabetic individuals reduces cardiovascular events. CGM may help identify dietary patterns driving glucose variability and insulin resistance, which may motivate behavior change, but the clinical outcome evidence does not yet exist at a level that constitutes a cardiovascular recommendation.

Who benefits from continuous glucose monitoring without diabetes?

Continuous glucose monitoring in non-diabetic individuals reveals postprandial glucose patterns that standard fasting glucose and HbA1c miss entirely. Studies show that glucose variability and postprandial spikes predict cardiovascular risk, non-alcoholic fatty liver disease, and future diabetes beyond fasting measures. In metabolically active individuals or those with risk factors for insulin resistance, CGM can identify dietary patterns that drive postprandial hyperglycemia, enabling targeted interventions before glycemic thresholds for prediabetes are crossed.

What is a normal glucose level after eating?

In metabolically healthy individuals, postprandial glucose peaks below 140 mg/dL (7.8 mmol/L) within 1 to 2 hours of eating and returns to below 100 mg/dL by 2 to 3 hours. Excursions above 140 mg/dL post-meal represent impaired postprandial glucose regulation even if fasting glucose is normal. Continuous glucose monitoring data from non-diabetic adults wearing CGM suggests that most meals in healthy individuals produce peaks below 120 mg/dL, with high glycemic index foods generating the largest excursions.

The System Gap

Continuous Glucose Monitoring for Men Without Diabetes. What It Actually Shows.

CGMs reveal glucose variability that fasting labs miss. A cardiologist reviews what the data is useful for in non-diabetic men and where the evidence runs out.

Job Mogire, MD, FACP, FACC · Medically reviewed June 14, 2026

Continuous glucose monitors worn by non-diabetic people have become part of the quantified health culture. The data they produce is real. What the data means for cardiovascular health in metabolically normal individuals requires careful context.

This article applies the same Honesty Scale rigor to CGM data as to every other clinical tool on this site. The device is not being dismissed. The evidence for specific claims is being examined by the same standard applied to everything here.

The consumer CGM market is growing rapidly, driven by endorsements from the longevity medicine community and a genuine public interest in understanding metabolic health in real time. Some of the enthusiasm is warranted. Some of it is ahead of the evidence. The goal here is to describe precisely where the line sits.

Who Benefits and Who Does Not

Before reviewing the mechanism and evidence, one framing point deserves explicit statement: the clinical utility of CGM in non-diabetic men is not uniform. It varies substantially based on where the individual sits on the metabolic spectrum, and the gap between the man who benefits most and the man who benefits least is large enough to matter in any honest clinical discussion of the technology.

The man with confirmed prediabetes, visceral adiposity, a fasting insulin of 14, and an HbA1c of 5.8 is using CGM for a purpose that has at least observational support and clinical plausibility. He has established metabolic dysfunction, and the CGM gives him personalized data on the dietary drivers of that dysfunction.

The metabolically healthy man with a waist circumference of 32 inches, fasting glucose of 82, fasting insulin of 5.5, and HbA1c of 5.0 will likely see a CGM trace that shows postprandial glucose rises to 115 to 130 mg/dL after most mixed meals, then returns to baseline within 90 minutes. This is normal physiology. The device will not reveal pathology that is not there. The primary risk for this individual is interpreting normal metabolic glucose dynamics as a problem requiring intervention.

The Mechanism

A CGM uses a small subcutaneous filament sensor to measure glucose concentration in the interstitial fluid continuously, typically every 1 to 5 minutes. The interstitial glucose reflects blood glucose with a physiological lag of approximately 5 to 15 minutes, particularly during periods of rapid glucose change such as immediately after a meal or during exercise. Consumer-grade devices including the Dexcom G7 and Abbott FreeStyle Libre Sense use electrochemical oxidase-based sensors. The G7’s accuracy data, published in Diabetes Technology and Therapeutics in 2023, showed a mean absolute relative difference (MARD) of 8.2 percent against reference blood glucose, which is adequate for diabetes management ranges but introduces meaningful uncertainty at the lower glucose concentrations common in non-diabetic individuals.

What the device measures is glucose kinetics: how fast glucose rises after a meal, how high it peaks, and how quickly it returns to baseline. The pattern of glucose rise and return is determined by several interacting factors. First, the glycemic index and glycemic load of the meal consumed: foods that deliver glucose rapidly into the portal circulation produce faster, higher peaks than foods that are absorbed more slowly. Second, the mass of carbohydrate consumed: even a low glycemic index food can produce a large excursion if consumed in large quantities. Third, the individual’s degree of insulin sensitivity: a man with normal insulin sensitivity clears postprandial glucose rapidly because his skeletal muscle is responsive to the insulin signal and takes up glucose efficiently. A man with insulin resistance clears it slowly because his cells do not respond adequately to the same insulin signal, and glucose remains elevated for longer.

This is the biological mechanism that gives CGM data potential clinical relevance in non-diabetic men: the postprandial glucose trace is a real-time indicator of insulin sensitivity operating on specific dietary inputs. A man who produces a glucose spike to 165 mg/dL after eating a bowl of rice and whose glucose remains above 140 at the two-hour mark is demonstrating impaired postprandial glucose tolerance, even if his fasting glucose is 94 and his HbA1c is 5.5. His static labs are within normal range. His dynamic response is not.

Insulin resistance develops in skeletal muscle first. The liver follows. By the time fasting glucose rises and HbA1c begins to creep upward, significant insulin resistance has often been present for years. The postprandial glucose response detected by a CGM sits earlier in this progression. It is not perfectly reliable as a diagnostic tool at the individual level, but it reflects a physiological reality that fasting labs genuinely miss. 3 / Early

The cardiovascular relevance of this mechanism is plausible and supported by epidemiological associations, but the causal chain from CGM-visible glucose variability to atherosclerosis progression in non-diabetic individuals is not yet established in interventional evidence. The DECODE Study Group analysis, published in Archives of Internal Medicine in 2001, found that two-hour postprandial glucose independently predicted cardiovascular mortality in non-diabetic adults beyond fasting glucose alone, across 20 European cohorts and more than 25,000 participants. This is association in observational data, not proof that CGM use or the dietary modifications it prompts will reduce those cardiovascular events. The distinction matters. 3 / Early

What the Evidence Shows

The strongest evidence for CGM use applies to diabetic patients. A 2019 randomized trial by Beck and colleagues published in JAMA, involving 158 adults with type 2 diabetes not on intensive insulin therapy, found that CGM use reduced HbA1c by 0.4 percentage points more than standard monitoring over 8 months. An earlier trial by Lind and colleagues published in JAMA in 2017, involving 161 adults with type 1 diabetes, found CGM reduced HbA1c by 0.43 percentage points over 52 weeks compared to conventional management. These are well-designed trials with meaningful clinical outcomes. The evidence in diabetic patients is substantial. 5 / Solid

For non-diabetic individuals, the trial evidence is substantially thinner. The most directly relevant published data comes from observational CGM studies rather than randomized trials measuring clinical outcomes. A 2020 study by Hall and colleagues published in Nature Metabolism followed 57 healthy volunteers wearing CGMs and found significant inter-individual variability in postprandial glucose responses to identical meals, including participants who showed glucose excursions above 140 mg/dL after standard reference meals despite normal HbA1c. This study has been widely cited by consumer CGM advocates. It establishes that glucose variability exists in non-diabetic individuals. It does not establish that detecting or modifying that variability reduces cardiovascular events. 3 / Early

The most frequently cited application of CGM in non-diabetic individuals is the identification of dietary patterns that produce glucose excursions, with the expectation that modifying those patterns reduces insulin resistance over time. The logic is sound. The clinical outcome data does not yet support it at the level of a cardiovascular recommendation. What exists is a plausible mechanism and preliminary observational associations. 2 / Theoretical

Consumer CGM accuracy in the normal glucose range deserves specific attention. The MARD figures cited by manufacturers are calculated primarily against reference measurements in the glucose range relevant to diabetes management, typically 70 to 400 mg/dL. At glucose concentrations below 100 mg/dL, which is where a metabolically normal man spends most of his time, sensor accuracy is lower. Fluctuations that appear on the CGM trace in the 70 to 95 mg/dL range may reflect sensor drift or physiological variation that the device cannot reliably distinguish. Interpreting these fluctuations as clinically meaningful can produce unnecessary anxiety and dietary restriction in men who are metabolically healthy.

The clinical utility of CGM therefore depends entirely on the metabolic state of the user and the interpretive framework applied to the data. For a man with confirmed prediabetes, glucose excursions above 140 after specific meals are informative and potentially motivating. For a man with fasting glucose of 84, HbA1c of 5.1, and fasting insulin below 8, the CGM trace will largely confirm normal physiology with some sensor noise included.

Cardiologist's Note

I have patients who find CGM data genuinely useful. They are almost uniformly men who were in a metabolic gray zone before wearing the device: prediabetic by HbA1c, with elevated fasting insulin, carrying visceral adiposity, and uncertain about which aspects of their diet were driving the problem. Two weeks of CGM in those men produces specific, behaviorally relevant information. The spike that hits 155 after the large bowl of oatmeal with fruit, the stability after the same breakfast with added protein and fat, the difference between two glasses of wine before bed and the overnight glucose pattern versus none: these are the kinds of specific findings that motivate dietary adjustment in ways that general carbohydrate restriction guidance does not.

The patients for whom I am more cautious are the metabolically normal men who arrive having already identified themselves as having “bad spikes.” They have read about glucose variability online, purchased a CGM, and are now tracking their glucose in the 80 to 110 mg/dL range and finding fluctuations that they interpret as pathological. Most of what they are seeing is normal postprandial physiology combined with sensor variation. The clinical harm here is not dramatic, but CGM anxiety is a real phenomenon. Men develop restrictive dietary patterns based on normal glucose responses, avoid foods they do not need to avoid, and generate clinical anxiety about measurements that do not carry the significance they are attributing to them.

The most appropriate use of CGM in non-diabetic men, in my practice, is time-limited: two weeks with a clear question in mind, ideally in a man with prediabetes or metabolic syndrome, interpreted against his fasting insulin, HbA1c, and waist circumference, not as a standalone surveillance tool. The device is informative as a diagnostic episode. It is less clearly useful as ongoing monitoring in men without a metabolic indication.

I want to be direct about what the evidence does not yet show: there are no published randomized trials demonstrating that CGM use in non-diabetic individuals reduces cardiovascular events, reduces progression to type 2 diabetes, or improves long-term metabolic outcomes beyond the duration of wear. The trial on which such a claim could rest has not been done. The mechanism is plausible. The claim is premature.

Time in Range: The CGM Metric That Adds Context to Fasting Lab Values

Time in range (TIR) refers to the percentage of a 24-hour period during which glucose values remain within a specified target band. For adults with type 1 or type 2 diabetes, the internationally agreed consensus target is glucose between 70 and 180 mg/dL for at least 70 percent of the day, with less than 4 percent of readings below 70 mg/dL. These thresholds were established by an international expert consensus panel in 2019 by Battelino and colleagues, published in Diabetes Care, synthesizing data from clinical trials and continuous glucose monitoring studies across tens of thousands of patient-days.

The clinical value of TIR comes from what it adds beyond HbA1c. HbA1c is a 90-day average that captures overall glycemic exposure but is insensitive to the shape of that exposure. A man with an HbA1c of 7.0 percent could be achieving that number through consistently moderate glucose values, or through swings between 50 and 250 mg/dL that average out to the same glycated hemoglobin percentage. Those two profiles carry different cardiovascular implications, and TIR distinguishes them.

Vigersky and McMahon, in Diabetes Technology and Therapeutics in 2019, analyzed the relationship between TIR and HbA1c across multiple CGM datasets and found that a 10 percentage point increase in TIR corresponds to approximately a 0.5-point reduction in HbA1c. Each 1 percent improvement in TIR approximates a 0.05 percent improvement in HbA1c. The relationship allows clinicians to translate real-time CGM data into a metric that aligns with a long-established cardiovascular risk marker.

Beck and colleagues, in a 2019 analysis published in JAMA, examined TIR as an endpoint in the DIAMOND trial, which had randomized adults with type 1 diabetes to CGM versus self-monitored blood glucose. The TIR analysis showed that CGM use increased TIR by approximately 3 percentage points compared to fingerstick testing, with the improvement correlating with HbA1c reduction. More importantly, the study validated TIR as a clinically meaningful endpoint that could stand alongside HbA1c in trial design, not merely as a surrogate measure.

For non-diabetic men using CGM, TIR targets shift. Glucose consistently between 70 and 140 mg/dL is typical in metabolically healthy individuals, with very few excursions above 140 mg/dL even after mixed meals. A man with metabolic syndrome or insulin resistance will often spend a detectable portion of each day above 140 mg/dL in the postprandial window. Quantifying that percentage gives a temporal picture that a single fasting glucose or HbA1c cannot.

The limitation in the non-diabetic range is sensor precision. Most CGM devices are validated against reference glucose measurements in the 70 to 180 mg/dL range. Accuracy is typically stated as mean absolute relative difference of 9 to 10 percent in clinical conditions. In the normal glucose range, where readings cluster near 80 to 120 mg/dL, that level of MARD introduces variation that can produce apparent fluctuations that are measurement artifact rather than true metabolic signal. TIR data in non-diabetic men therefore requires clinical interpretation alongside validated lab markers rather than standing alone as a risk verdict.

What to Do This Week

If you have prediabetes (fasting glucose 100 to 125, or HbA1c 5.7 to 6.4) or confirmed metabolic syndrome, discuss a two-week CGM trial with your physician as a diagnostic tool for identifying specific dietary patterns that drive glucose excursions. Go in with a specific question: which meals are producing postprandial glucose above 140 mg/dL at the two-hour mark? Let that answer guide dietary modification, then follow up with repeat fasting insulin and HbA1c at three months.
Before wearing a CGM, establish your baseline metabolic labs: fasting insulin, fasting glucose, and HbA1c together. The CGM trace means different things depending on where those numbers sit. A glucose excursion to 145 mg/dL after a meal means something different in a man with fasting insulin of 18 than in a man with fasting insulin of 6.
If you are considering a consumer CGM and are metabolically normal by lab standards, frame your question narrowly before you start. What specific dietary or behavioral change will you make based on what you see? If the answer is not specific, the data is more likely to produce noise than signal.
Do not use CGM as a replacement for the established metabolic cardiovascular risk markers. Fasting insulin, HbA1c, and fasting glucose together form a more clinically validated picture of metabolic cardiovascular risk than CGM data alone. CGM supplements this foundation for specific diagnostic purposes. It does not replace it.
If you identify consistent postprandial spikes above 140 mg/dL, the most evidence-supported dietary modifications are reducing refined carbohydrate load at individual meals, increasing dietary protein and fat as substitutes (which slow gastric emptying and reduce glucose absorption rate), and timing moderate-intensity physical activity within 30 to 60 minutes after large carbohydrate meals. These interventions have trial evidence for improving postprandial glucose. The CGM is a useful tool for seeing whether they are working for you specifically.

The glucose variability that a CGM reveals is real physiology. Whether detecting it and modifying diet in response will reduce cardiovascular events in non-diabetic men is a question that clinical trials have not yet answered. The honest position is to use the data where it is clearly informative, acknowledge where the evidence runs out, and avoid claiming clinical certainty that the trial record does not yet support.

The Signal Check is fifteen questions mapping the male cardiovascular risk pattern, including the physiological domains most commonly missed in standard screenings. It produces a specific starting point for your next clinical conversation.

Start with the gap between how you appear and what your body is doing.

Take the Signal Check

Did this land?

The conversation

Join the men working through this in the open.